NanoTemper Technologies

Protein production teams, get ready to move faster and more efficiently to deliver high-quality recombinant proteins! We’re excited to bring you Andromeda X, now with Spectral Shift technology, to help you optimize protein expression for all of your drug discovery workflows. Learn more: https://bit.ly/3whayEf

Our mission is to enable researchers to create a world where every disease is treatable, and every paper that our customers publish brings us one step closer to that goal. Thank you to the incredible scientists who trust our technologies to advance their research 🚀

1,000,000 hours more time for drug discovery A huge number. When you are 80 years old, your life has had 700,800 hours. How is it then possible to achieve ONE million more hours for drug discovery? My family suffers from cancer. I am afraid of cancer. I don’t want to be a victim of fate. I want to do something. Act. Develop a drug vs cancer? My life my be to short. Only 700k hours. Where is my leverage? How can I have a big impact? Biophysical tools for drug discovery. We now have 20,000 users of our tools. Assume every user works 50 weeks per year. Our tools are plug and play. Robust. Easy to learn and use. Our good user experience saves everyone at least 1 hour per week. 20,000 user x 50 weeks x 1 hour saving per week. This is 1,000,000 hours per year more time. 1,000,000 hours more for science. More than a lifetime. This is just a small part of the value we bring into life sciences. And even this has a huge impact. What we do her matter. Biophysical tools matter. Biotech matters. Your science matters. Be aware of it. You are doing great! #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

High-resolution stability data on your mAbs candidates is critical to their success at clinical stages. See why scientists like Elsa Wagner from Pierre Fabre Group choose Prometheus Panta – a tool for multi-parameter stability characterization – for confident developability assessment of their candidates.

From 7 weeks to 48 hours: our journey to lightning-fast delivery When you order something, you want to have it. And you want to have it soon. The last years, it took us 7 weeks on average to ship our devices to EU and US customers. This was slow. This was not as fast, as our customer wanted and needed it. This was bad. Today, we've cut that down to just 48 hours: 48 hours from receiving an order to shipping the instrument. How did we do it in just six months? 1. Streamlined Operations: Enabled better demand planning and streamlined our production. 2. Enhanced Efficiency: Optimized our process flows and automated key steps. 3. Teamwork Makes the Dream Work: None of this would be possible without our incredible team and their seamless collaboration. This isn't just a win for us. It is a huge leap forward for our customers. We ensure that you get what you need faster than ever. Proud of our team and what we've achieved together! #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

Could targeted protein degradation (TPD) be the key to treating neurodegenerative diseases (NDs) like Alzheimer’s and Parkinson’s? Most TPD research has focused on combatting cancer, but proof-of-concept studies have already shown that degraders are a viable modality to treat NDs. However, some challenges need to be addressed before degraders targeting NDs can reach the clinic. Things like the blood-brain barrier and lack of central nervous system specific E3 ligases make degrader development for NDs tricky. This mini-review published in Frontiers in Molecular Neurosciences explores the therapeutic potential of PROTACs and molecular glues for NDs, highlighting their advantages over traditional small molecule inhibitors and the challenges ahead. Read the full publication here: https://lnkd.in/gJTEZTw7

When screening fragments, it's critical to distinguish true hits from artifacts so you maximize the chances of creating a successful therapeutic. So, what should you consider when choosing hit cut-offs during single-dose screens?     R&D scientist Nathan Adams from NanoTemper shares his insights on identifying true hits with Spectral Shift technology.

G Protein-Coupled Receptors (GPCRs) are well-established as effective drug targets, but their inherent complexity poses significant challenges for binding measurements. Here are four reasons why conventional methods often fall short and why alternative approaches are essential: 1️⃣ GPCRs are membrane proteins: GPCRs are membrane-bound, making them amphipathic and challenging to solubilize. Traditional techniques often fail to maintain their solubility, leading to unreliable results. Advanced methods are required to handle these solubility challenges effectively. 2️⃣ GPCRs have a complex structure: The structural intricacies of GPCRs are difficult to study in isolation. Their dynamic nature means that traditional static analysis techniques can't capture the full picture. Innovative technologies that allow for real-time, structural analysis are needed to better understand these receptors. 3️⃣ GPCRs display intricate modes of action: GPCRs engage in complex signaling pathways, including dimerization, transduction, and three-way interactions. Traditional binding studies can overlook these multifaceted interactions. Comprehensive approaches that account for these complexities are essential for accurate drug targeting. 4️⃣ GPCRs need alternative expression strategies The difficulty in producing GPCRs in high yields leads to reliance on alternative expression systems, often resulting in lower yields and the need for detergent-heavy buffers. This makes it crucial to use methods that maximize receptor production while preserving function. If you're working with GPCRs, how do you currently address the challenges above?

Working on developing your next bispecific antibody? In a recent publication scientists from DTU - Technical University of Denmark describe a comprehensive set of complementary methods to study Bispecific mAbs critical quality attributes (CQAs) including thermal stability and aggregation propensity. Among other tools, their study highlight the value of Prometheus Panta for simultaneous thermal and colloidal stability measurements with high-throughput and very low material consumption, crucial in the developability assessment of bispecifics. The authors state "Importantly, the simultaneous monitoring of aggregation during unfolding, as illustrated in Figure 2, favors in-depth understanding of the antibody behavior and developability profile." Read the publication here: https://lnkd.in/eybphcZY

Hot off the press excitement for #structuralbiology combining NanoTemper Technologies label-free thermal unfolding #nanoDSF with #CryoEM! 🎆 A global team of researchers from Stockholm University, Harvard University, Boston Children's Hospital and Ipsen Bioinnovation just published this exciting work in Nature Portfolio's Communication Chemistry investigating a new botulinum neurotoxin serotype, BoNT/X, with promising therapeutic properties, and how the presence or absence of it's protective partner protein (NTNH) that stabilized the BoNT/X affects potency. Read more about this exciting #research here: https://lnkd.in/g9rfPNv8 #biophysics #protein #toxin #therapeutic #teamwork